Immune Design (Immune Design) Days Sales Outstanding : 142.34 (As of Dec. 2018)

View and export this data going back to 2014. Start your Free Trial

What is Immune Design Days Sales Outstanding?

Immune Design's average Accounts Receivable for the three months ended in Dec. 2018 was $0.74 Mil. Immune Design's Revenue for the three months ended in Dec. 2018 was $0.48 Mil. Hence, Immune Design's Days Sales Outstanding for the three months ended in Dec. 2018 was 142.34.

The historical rank and industry rank for Immune Design's Days Sales Outstanding or its related term are showing as below:

IMDZ's Days Sales Outstanding is not ranked ^*
in the Biotechnology industry.
Industry Median: 72.19
* Ranked among companies with meaningful Days Sales Outstanding only.

Immune Design's Days Sales Outstanding increased from Dec. 2017 (109.78) to Dec. 2018 (142.34).

Immune Design Days Sales Outstanding Historical Data

The historical data trend for Immune Design's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immune Design Days Sales Outstanding Chart

Immune Design Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Days Sales Outstanding

Get a 7-Day Free Trial

58.36

56.46

20.49

29.52

112.36

Immune Design Quarterly Data
	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18
Days Sales Outstanding	Get a 7-Day Free Trial															109.78	89.53	60.43	142.21	142.34

Competitive Comparison of Immune Design's Days Sales Outstanding

For the Biotechnology subindustry, Immune Design's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immune Design's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immune Design's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Immune Design's Days Sales Outstanding falls into.

Immune Design Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Immune Design's Days Sales Outstanding for the fiscal year that ended in Dec. 2018 is calculated as

	Days Sales Outstanding (A: Dec. 2018 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2017 )	+	Accounts Receivable (A: Dec. 2018 ))	/	count )	/	Revenue (A: Dec. 2018 )	*	Days in Period
=	( (0.647	+	0.705)	/	2 )	/	2.196	*	365
=	0.676					/	2.196	*	365
=	112.36

Immune Design's Days Sales Outstanding for the quarter that ended in Dec. 2018 is calculated as:

	Days Sales Outstanding (Q: Dec. 2018 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2018 )	+	Accounts Receivable (A: Dec. 2018 ))	/	count )	/	Revenue (A: Dec. 2018 )	*	Days in Period
=	( (0.78	+	0.705)	/	2 )	/	0.476	*	365 / 4
=	0.7425					/	0.476	*	365 / 4
=	142.34

Immune Design (NAS:IMDZ) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Immune Design Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Immune Design's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Immune Design (Immune Design) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immune Design Corp (NAS:IMDZ) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

1616 Eastlake Avenue East, Suite 310, Seattle, WA, USA, 98102

Website

http://www.immunedesign.com

Immune Design is a clinical-stage immunotherapy company. Its focus is next-generation in vivo methods intended to enable the body's immune system to fight diseases. The company's therapies have a broad potential approach across multiple therapeutic areas. Nevertheless, the company's target is oncology, and it is developing tumor-specific cytotoxic T cells to fight cancer. The main discoveries are CMB305 and G100, immuno-oncology approaches that are believed to address the shortcomings of existing oncological therapies.

Executives

William R Ringo	director
David Baltimore	director	AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Edward Penhoet	director	ONE EMBARCADERO CENTER SUITE 3700, SAN FRANCISCO CA 94111
Susan L. Kelley	director	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Carlos V Paya	director, officer: President and CEO	C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E, SUITE 310, SEATTLE WA 98102
David V Goeddel	10 percent owner, other: Managing Partner	C/O COLUMN GROUP LP, 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Ii, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Peter Svennilson	10 percent owner, other: Managing Partner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Tim Kutzkey	10 percent owner, other: Managing Partner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Ii Gp, Lp	10 percent owner, other: General Partner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Ponoi Capital, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Ponoi Management, Llc	10 percent owner, other: General Partner	1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129
Column Group L P	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Gp, Lp	10 percent owner, other: General Partner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Franklin M Berger	director	1000 MARINA BLVD, STE 200, BRISBANE CA 94005